- Home
- HIVE vs ZBIO Comparison
HIVE vs ZBIO Comparison
Compare HIVE & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- ZBIO
- Stock Information
- Founded
- HIVE 1987
- ZBIO 2019
- Country
- HIVE Canada
- ZBIO United States
- Employees
- HIVE N/A
- ZBIO N/A
- Industry
- HIVE
- ZBIO
- Sector
- HIVE
- ZBIO
- Exchange
- HIVE Nasdaq
- ZBIO NYSE
- Market Cap
- HIVE 376.8M
- ZBIO 389.2M
- IPO Year
- HIVE N/A
- ZBIO 2024
- Fundamental
- Price
- HIVE $1.70
- ZBIO $9.19
- Analyst Decision
- HIVE Strong Buy
- ZBIO Strong Buy
- Analyst Count
- HIVE 7
- ZBIO 7
- Target Price
- HIVE $7.64
- ZBIO $32.29
- AVG Volume (30 Days)
- HIVE 17.3M
- ZBIO 202.0K
- Earning Date
- HIVE 08-11-2025
- ZBIO 08-16-2025
- Dividend Yield
- HIVE N/A
- ZBIO N/A
- EPS Growth
- HIVE N/A
- ZBIO N/A
- EPS
- HIVE N/A
- ZBIO N/A
- Revenue
- HIVE $120,999,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- HIVE $1.87
- ZBIO $206.00
- Revenue Next Year
- HIVE $164.35
- ZBIO $41.92
- P/E Ratio
- HIVE N/A
- ZBIO N/A
- Revenue Growth
- HIVE 26.29
- ZBIO N/A
- 52 Week Low
- HIVE $1.26
- ZBIO $5.83
- 52 Week High
- HIVE $5.54
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- HIVE 38.81
- ZBIO N/A
- Support Level
- HIVE $1.86
- ZBIO N/A
- Resistance Level
- HIVE $1.98
- ZBIO N/A
- Average True Range (ATR)
- HIVE 0.11
- ZBIO 0.00
- MACD
- HIVE -0.03
- ZBIO 0.00
- Stochastic Oscillator
- HIVE 5.98
- ZBIO 0.00
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.